Genesis Therapeutics is a team of drug hunters, deep learning researchers, and software engineers collaborating to drive AI in biochemistry, discovering and developing new therapies for patients suffering from severe disorders.

Genesis Therapeutics

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery.

The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. 

We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020).

Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

T. Rowe Price

Ulu Ventures

Felicis

Rock Springs Capital

Open Field Capital

Propagator Ventures

Radical Ventures

Jazz Venture Partners

Menlo Ventures

Jeffrey Rothschild

BlackRock

Fidelity

Andreessen Horowitz

Fidelity Management and Research Company

Next week, Genesis’ CEO, Dr. Evan Feinberg, PhD, will speak at the 2024 WuXi AppTec Global Forum alongside fellow industry leaders to discuss how platform solutions, such as Genesis’ AI-enabled drug discovery platform, are driving the development of medicines that improve the lives of patients living with difficult-to-treat disease.

Learn more about the panel, “Delivering on Platform Solutions,” and the forum here: https://lnkd.in/ggbqGe2F

A few members of our technical team will be at MoML tomorrow. We’re looking forward to learning about the latest in molecular ML and connecting with old and new fiends. Come say hi 👋, find out what our team has been up to 🤓, and learn about opportunities at Genesis! 🚀

Genesis’ CEO and co-founder Evan Feinberg sat down with a16z Bio + Health and Health’s Vijay Pande, PhD on this week’s episode of Bio Eats World to discuss AI in small-molecule drug design and the founding of Genesis, from Evan’s early days at Stanford to the company’s recent $200M series B.

Listen to the podcast episode here: https://lnkd.in/g6-Zv-kQ

Genesis is excited to announce $200 million in Series B funding, which we’ll use to supercharge our AI platform and accelerate our pipeline with an eye toward the clinic.

Read more in today’s press release: https://lnkd.in/g3utJ3W9

Metric
Company Name	Genesis Therapeutics
Symbol
MSH ID	AI:GENESISTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	69
Website	genesistherapeutics.ai
LinkedIn	genesistherapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AI:GENESISTHERAPEUTICS

Genesis Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue